Research progress of precise targeted therapy for human epidermal growth factor receptor-2 in biliary tract cancers / 中华肝胆外科杂志

ABSTRACT

Biliary tract cancers (BTC) are highly heterogeneous tumours. Currently, the global demand for advanced BTC treatment is far from being met, and the survival benefit from advanced chemotherapy is limited. In recent years, with the rise of precision treatment, there are more and more treatment options available for advanced BTC. Human epidermal growth factor receptor-2 (HER2) inhibitors, including monoclonal antibodies, tyrosine kinase inhibitors, antibody drug conjugates, and bispecific antibodies, have been explored in BTC. This article reviews the research progress and prospects of HER2 inhibitors in BTC in recent years, so as to provide a better clinical guidance.